title: Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
abstract: Conflicting reports of the necessity for percutaneous bacillus Calmette-Guerin (BCG) administration with intravesical BCG prompted us to evaluate its benefit in a randomized prospective comparison of intravesical versus intravesical with percutaneous BCG therapy. Intravesical Tice BCG was given in a dose of 50 mg. with or without percutaneous BCG weekly for 6 weeks, at 8, 10 and 12 weeks, at 6 months and every 6 months thereafter. Tumor recurrence was documented in 13 of 30 patients (43%) receiving only intravesical BCG and in 15 of 36 patients (42%) receiving intravesical plus percutaneous BCG. The addition of percutaneous BCG to intravesical therapy did not increase treatment efficacy in this study.
authors.affiliation: Department of Urology, West Virginia University Health Sciences Center, Morgantown.
authors.forename: D L
authors.initials: DL
authors.lastname: Lamm
authors.forename: J I
authors.initials: JI
authors.lastname: DeHaven
authors.forename: J
authors.initials: J
authors.lastname: Shriver
authors.forename: M F
authors.initials: MF
authors.lastname: Sarosdy
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000473:pathology / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008297:Male; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D001500:BCG Vaccine